Moleculin Biotech (MBRX) Competitors $0.40 -0.20 (-33.64%) As of 03:01 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MBRX vs. ARTV, RPTX, OVID, MNOV, INMB, ELYM, IMMX, ANL, GNTA, and GANXShould you be buying Moleculin Biotech stock or one of its competitors? The main competitors of Moleculin Biotech include Artiva Biotherapeutics (ARTV), Repare Therapeutics (RPTX), Ovid Therapeutics (OVID), MediciNova (MNOV), INmune Bio (INMB), Eliem Therapeutics (ELYM), Immix Biopharma (IMMX), Adlai Nortye (ANL), Genenta Science (GNTA), and Gain Therapeutics (GANX). These companies are all part of the "pharmaceutical products" industry. Moleculin Biotech vs. Its Competitors Artiva Biotherapeutics Repare Therapeutics Ovid Therapeutics MediciNova INmune Bio Eliem Therapeutics Immix Biopharma Adlai Nortye Genenta Science Gain Therapeutics Moleculin Biotech (NASDAQ:MBRX) and Artiva Biotherapeutics (NASDAQ:ARTV) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability. Does the media prefer MBRX or ARTV? In the previous week, Moleculin Biotech had 3 more articles in the media than Artiva Biotherapeutics. MarketBeat recorded 6 mentions for Moleculin Biotech and 3 mentions for Artiva Biotherapeutics. Artiva Biotherapeutics' average media sentiment score of 1.41 beat Moleculin Biotech's score of 0.62 indicating that Artiva Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moleculin Biotech 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Artiva Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders and institutionals have more ownership in MBRX or ARTV? 15.5% of Moleculin Biotech shares are owned by institutional investors. 2.1% of Moleculin Biotech shares are owned by company insiders. Comparatively, 21.4% of Artiva Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is MBRX or ARTV more profitable? Artiva Biotherapeutics' return on equity of -42.60% beat Moleculin Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Moleculin BiotechN/A -1,498.41% -114.47% Artiva Biotherapeutics N/A -42.60%-37.76% Do analysts recommend MBRX or ARTV? Moleculin Biotech presently has a consensus price target of $4.00, suggesting a potential upside of 892.56%. Artiva Biotherapeutics has a consensus price target of $17.00, suggesting a potential upside of 427.13%. Given Moleculin Biotech's higher possible upside, equities analysts clearly believe Moleculin Biotech is more favorable than Artiva Biotherapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moleculin Biotech 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Artiva Biotherapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has better valuation & earnings, MBRX or ARTV? Moleculin Biotech has higher earnings, but lower revenue than Artiva Biotherapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoleculin BiotechN/AN/A-$21.76MN/AN/AArtiva Biotherapeutics$250K315.15-$65.37MN/AN/A SummaryArtiva Biotherapeutics beats Moleculin Biotech on 6 of the 10 factors compared between the two stocks. Get Moleculin Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for MBRX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MBRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MBRX vs. The Competition Export to ExcelMetricMoleculin BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.21M$3.06B$5.75B$9.85BDividend YieldN/A2.26%3.95%4.02%P/E RatioN/A21.1531.3126.63Price / SalesN/A383.94459.79120.56Price / CashN/A44.4437.7659.36Price / Book-1.688.0810.026.70Net Income-$21.76M-$54.08M$3.27B$265.68M7 Day Performance-32.46%2.44%3.26%3.46%1 Month Performance-26.77%3.56%4.45%1.11%1 Year Performance-83.94%18.78%44.34%24.00% Moleculin Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MBRXMoleculin Biotech2.8895 of 5 stars$0.40-33.6%$4.00+892.6%-75.4%$12.21MN/A0.0020News CoverageAnalyst ForecastGap DownHigh Trading VolumeARTVArtiva Biotherapeutics3.3328 of 5 stars$2.76-1.1%$17.00+516.2%-69.4%$66.67M$250K0.0081Positive NewsRPTXRepare Therapeutics2.8238 of 5 stars$1.55+1.3%$4.50+190.3%-45.5%$66.59M$53.48M-0.60180OVIDOvid Therapeutics4.183 of 5 stars$0.93-1.1%$3.10+233.3%-1.6%$66.28M$570K-1.7660Analyst RevisionMNOVMediciNova2.2242 of 5 stars$1.32+1.5%$7.00+430.3%-8.2%$64.25M$1M-5.2810Analyst ForecastGap UpINMBINmune Bio2.0046 of 5 stars$2.37-1.5%$18.40+678.0%-71.0%$62.87M$50K-0.9510Positive NewsELYMEliem TherapeuticsN/A$2.11+11.1%N/A-59.1%$62.78MN/A-3.989Positive NewsGap UpHigh Trading VolumeIMMXImmix Biopharma3.343 of 5 stars$2.18-0.7%$7.00+221.8%-10.1%$62.71MN/A-2.829Analyst DowngradeANLAdlai Nortye1.6454 of 5 stars$1.70-0.3%$9.00+431.0%-43.5%$62.55MN/A0.00127Positive NewsGap DownGNTAGenenta Science2.3507 of 5 stars$3.39-0.6%$25.00+637.5%-7.8%$62.00MN/A0.007News CoverageGANXGain Therapeutics2.1783 of 5 stars$1.71+1.2%$7.80+356.1%+42.0%$61.47MN/A-2.7120News CoverageAnalyst Revision Related Companies and Tools Related Companies ARTV Competitors RPTX Competitors OVID Competitors MNOV Competitors INMB Competitors ELYM Competitors IMMX Competitors ANL Competitors GNTA Competitors GANX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MBRX) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAmazon’s big Bitcoin embarrassmentBitcoin just passed Amazon in total market cap — but most investors are missing the bigger opportunity. Whi...Brownstone Research | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Moleculin Biotech, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Moleculin Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access